More patients treated with ZTlido ® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5% ... non-opioid pain management products for ...

Mean pain severity was mild at the most in high dose group versus severe in placebo group ... in parallel development for treatment of acute and chronic pain conditions. Due to its dual mechanism ...

Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.

More patients treated with ZTlido® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).Of all study patients reporting a ...

“Mean pain severity was mild at the most in [the] high-dose group versus ... acute pain (defined as lasting less than 3 months), follow positive Phase IIb trial results of XG005 treatment in ...

Haleon's global business lead for the Pain Portfolio & Systemics shares key consumer health trends reshaping the healthcare ...

Physician empathy has long been recommended — but not required — in the doctor-patient relationship.However, for a growing ...

When untreated, this injury may lead to decreased pinch strength, pain, instability, and osteoarthritis. There is currently no consensus on treatment of acute or chronic UCL injuries. Our primary ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

A study of nearly 1,000 people with post-COVID-19 syndrome (PCS) revealed that two-thirds still experienced significant symptoms, including reduced exercise capacity and cognitive performance, two ...

The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure long term sustainable growth, Juneja stated.